Quick Read Hims & Hers (HIMS) missed Q1 2026 on revenue ($608.1M vs. consensus $616.85M) and earnings (-$0.40 EPS vs.

Shares of Hims & Hers Health (NYSE:HIMS) are under pressure after JPMorgan trimmed its price target on the consumer telehealth name following a messy first quarter. The firm lowered its price target ...

The average one-year price target for Hims & Hers Health (NYSE:HIMS) has been revised to $30.00 / share. This is a decrease of 30.94% from the prior estimate of $43.45 dated February 1, 2026. The ...

BofA cut its HIMS price target to $25 from $28, while warning that the company’s 2026 outlook depends on a “significant” ramp ...

Hims & Hers Health, Inc. (NYSE:HIMS) is among the 10 Fastest Growing NYSE Stocks to Buy. On February 24, 2026, Barclays lowered its price target on Hims & Hers Health, Inc. (NYSE:HIMS) to $25 from $48 ...

Hims & Hers Health, Inc. (NYSE:HIMS) ranks among the most shorted stocks to buy according to analysts. Following Novo Nordisk’s lawsuit against Hims & Hers Health, Inc. (NYSE:HIMS), Canaccord Genuity ...

Key Points Interested in Hims & Hers Health, Inc.? Here are five stocks we like better. Hims & Hers Health plans to acquire ...

Last Thursday, Hims & Hers Health announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Novo Nordisk’s ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Hims & Hers also said it is shifting its U.S. weight-loss business away from actively advertising compounded GLP-1 drugs and toward a wider assortment of FDA-approved treatments. Existing patients may ...